Assembly Biosciences (ASMB) Competitors

$22.54 -0.44 (-1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$22.49 -0.05 (-0.22%)

As of 04:15 PM Eastern

ASMB vs. CMPS, ANIP, ETON, GHRS, and XERS

Should you buy Assembly Biosciences stock or one of its competitors? Assembly Biosciences's main competitors and comparable companies include Compass Pathways (CMPS), ANI Pharmaceuticals (ANIP), Eton Pharmaceuticals (ETON), GH Research (GHRS), and Xeris Biopharma (XERS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Compass Pathways?

Assembly Biosciences (NASDAQ:ASMB) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Assembly Biosciences has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Assembly Biosciences currently has a consensus target price of $47.50, indicating a potential upside of 113.34%. Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 95.39%. Given Assembly Biosciences' higher probable upside, research analysts clearly believe Assembly Biosciences is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Assembly Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market.

Compass Pathways has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Compass Pathways	N/A	-49.63%	-13.08%

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Pathways had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Compass Pathways and 0 mentions for Assembly Biosciences. Compass Pathways' average media sentiment score of 0.35 beat Assembly Biosciences' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Compass Pathways	Neutral

Summary

Assembly Biosciences beats Compass Pathways on 8 of the 15 factors compared between the two stocks.

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Assembly Biosciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Assembly Biosciences. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 0 mentions for Assembly Biosciences. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Assembly Biosciences' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
ANI Pharmaceuticals	Positive

Assembly Biosciences presently has a consensus target price of $47.50, indicating a potential upside of 113.34%. ANI Pharmaceuticals has a consensus target price of $98.00, indicating a potential upside of 36.17%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

ANI Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83
ANI Pharmaceuticals	$883.37M	1.87	$78.34M	$4.64	15.51

ANI Pharmaceuticals has a net margin of 11.07% compared to Assembly Biosciences' net margin of -0.06%. ANI Pharmaceuticals' return on equity of 27.37% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

ANI Pharmaceuticals beats Assembly Biosciences on 10 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Eton Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Eton Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83
Eton Pharmaceuticals	$79.95M	19.33	-$4.60M	$0.38	142.32

Assembly Biosciences currently has a consensus price target of $47.50, indicating a potential upside of 113.34%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 24.81%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Assembly Biosciences is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Eton Pharmaceuticals has a net margin of 12.02% compared to Assembly Biosciences' net margin of -0.06%. Eton Pharmaceuticals' return on equity of 40.13% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Eton Pharmaceuticals and 0 mentions for Assembly Biosciences. Eton Pharmaceuticals' average media sentiment score of 0.71 beat Assembly Biosciences' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Eton Pharmaceuticals	Positive

Assembly Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to GH Research?

GH Research (NASDAQ:GHRS) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, GH Research had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 1 mentions for GH Research and 0 mentions for Assembly Biosciences. GH Research's average media sentiment score of 0.67 beat Assembly Biosciences' score of 0.00 indicating that GH Research is being referred to more favorably in the media.

Company	Overall Sentiment
GH Research	Positive
Assembly Biosciences	Neutral

Assembly Biosciences has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83

GH Research presently has a consensus target price of $45.00, indicating a potential upside of 100.04%. Assembly Biosciences has a consensus target price of $47.50, indicating a potential upside of 113.34%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

GH Research has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

56.9% of GH Research shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GH Research has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

Assembly Biosciences beats GH Research on 9 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Xeris Biopharma?

Assembly Biosciences (NASDAQ:ASMB) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Assembly Biosciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Assembly Biosciences presently has a consensus price target of $47.50, indicating a potential upside of 113.34%. Xeris Biopharma has a consensus price target of $12.80, indicating a potential upside of 40.61%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Assembly Biosciences is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Xeris Biopharma had 13 more articles in the media than Assembly Biosciences. MarketBeat recorded 13 mentions for Xeris Biopharma and 0 mentions for Assembly Biosciences. Xeris Biopharma's average media sentiment score of 0.64 beat Assembly Biosciences' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Xeris Biopharma	Positive

Assembly Biosciences has a net margin of -0.06% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Xeris Biopharma	-5.12%	338.21%	3.50%

Xeris Biopharma has higher revenue and earnings than Assembly Biosciences. Xeris Biopharma is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.83
Xeris Biopharma	$291.85M	5.69	$550K	-$0.11	N/A

Summary

Assembly Biosciences and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$458.91M	$12.22B	$7.11B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.88%
P/E Ratio	22.10	797.14	274.42	26.03
Price / Sales	6.35	751.87	600.72	89.51
Price / Cash	N/A	81.79	77.38	51.25
Price / Book	1.73	10.47	10.92	6.32
Net Income	-$6.12M	$2.83B	$3.50B	$361.43M
7 Day Performance	-4.77%	-1.64%	-2.07%	-1.66%
1 Month Performance	-38.62%	-5.80%	-6.32%	-3.93%
1 Year Performance	-4.89%	-3.84%	8.92%	2.82%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	2.6112 of 5 stars	$22.54 -1.9%	$47.50 +110.7%	-6.6%	$458.91M	$72.30M	22.10	73
CMPS Compass Pathways	2.3013 of 5 stars	$13.09 -4.8%	$23.36 +78.4%	+107.1%	$1.81B	N/A	N/A	156	News Coverage
ANIP ANI Pharmaceuticals	4.4483 of 5 stars	$74.04 -0.5%	$98.00 +32.4%	-19.1%	$1.70B	$978.38M	15.96	970	Insider Trade
ETON Eton Pharmaceuticals	4.3893 of 5 stars	$59.49 +7.0%	$67.50 +13.5%	+156.6%	$1.70B	$105.60M	156.55	44
GHRS GH Research	3.0414 of 5 stars	$24.45 -5.8%	$45.00 +84.0%	+68.5%	$1.68B	N/A	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. CMPS, ANIP, ETON, GHRS, and XERS

How does Assembly Biosciences compare to Compass Pathways?

Summary

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eton Pharmaceuticals?

Summary

How does Assembly Biosciences compare to GH Research?

Summary

How does Assembly Biosciences compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. CMPS, ANIP, ETON, GHRS, and XERS

How does Assembly Biosciences compare to Compass Pathways?

Which has higher earnings and valuation, ASMB or CMPS?

Do analysts rate ASMB or CMPS?

Which has more risk and volatility, ASMB or CMPS?

Is ASMB or CMPS more profitable?

Do institutionals & insiders have more ownership in ASMB or CMPS?

Does the media refer more to ASMB or CMPS?

Summary

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Do insiders and institutionals have more ownership in ASMB or ANIP?

Which has more volatility & risk, ASMB or ANIP?

Does the media favor ASMB or ANIP?

Do analysts recommend ASMB or ANIP?

Which has better earnings and valuation, ASMB or ANIP?

Is ASMB or ANIP more profitable?

Summary

How does Assembly Biosciences compare to Eton Pharmaceuticals?

Which has stronger earnings and valuation, ASMB or ETON?

Do analysts recommend ASMB or ETON?

Is ASMB or ETON more profitable?

Do institutionals & insiders believe in ASMB or ETON?

Does the media prefer ASMB or ETON?

Which has more risk and volatility, ASMB or ETON?

Summary

How does Assembly Biosciences compare to GH Research?

Does the media refer more to GHRS or ASMB?

Which has higher earnings and valuation, GHRS or ASMB?

Do analysts prefer GHRS or ASMB?

Is GHRS or ASMB more profitable?

Do insiders and institutionals hold more shares of GHRS or ASMB?

Which has more volatility & risk, GHRS or ASMB?

Summary

How does Assembly Biosciences compare to Xeris Biopharma?

Which has more volatility and risk, ASMB or XERS?

Do analysts recommend ASMB or XERS?

Do insiders and institutionals have more ownership in ASMB or XERS?

Does the media refer more to ASMB or XERS?

Is ASMB or XERS more profitable?

Which has stronger valuation & earnings, ASMB or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools